Abstract: Objective To observe the expression and and clinical significance of long non-coding RNA (lncRNA) ANRIL and miR-191 in the plasma of patients with non-small cell lung cancer (NSCLC).Methods 153 patients with NSCLC first diagnosed in our hospital from May 2015 to August 2017 and 75 healthy physical examiners were selected.Plasma ANRIL and miR-191 levels were detected by quantitative real-time fluorescence PCR (qRT-PCR).The relationship between ANRIL and miR-191 expression levels and clinicopathological characteristics was analyzed.Kaplan-Meier was used to analyze the relationship between ANRIL and miR-191 expression levels and prognosis.COX regression was used to analyze the risk factors for poor prognosis of NSCLC patients.Results Plasma ANRIL (3.09±0.53) and miR-191 (2.82±0.47) levels were higher in NSCLC patients than in the normal population (0.64±0.04) and (0.42±0.07) (P<0.05).Plasma ANRIL and miR191 levels were higher in patients with low to moderate differentiation,stage Ⅲ+Ⅳ,and lymph node metastasis than in patients with high differentiation,stage Ⅰ+Ⅱ,and no lymph node metastasis (all P<0.05).5-year overall survival (OS) was lower in patients in the high ANRIL expression group (37/83,44.58%),the miR-191 high expression group (40/79,50.63%)than in the low ANRIL expression group (48/65,73.85%),the miR-191 low expression group (49/69,71.01%) (both P<0.05).Stage Ⅲ+Ⅳ,presence of lymph node metastasis,high plasma ANRIL expression and high plasma miR-191 expression were independent risk factors for poor prognosis in NSCLC patients (all P<0.05).Conclusion High plasma ANRIL and miR-191 expression in NSCLC patients were associated with stage,lymph node metastasis,differentiation degree and prognosis.

Key words: non-small cell lung cancer, microRNA-191, long non-coding RNA ANRIL, prognosis